The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2008Evaluation of LRRK2 Inhibitors in the LRRK2 Drosophila PD Model
Objective/Rationale:
Biochemical evidence suggests that aberrant GTPase and kinase activities are linked to disease causing mutations in LRRK2, and may be at the basis of neuronal toxicity and... -
Rapid Response Innovation Awards, 2008Bee Venom as a Neuroprotective Agent in Parkinson's Disease
Objective/Rationale:
Based on a serendipitous obsrevation in one patient with Parkinson’s disease (PD), resaerchers wish to verify, in a pre-clinical model of the disease, whether bee venom and one of... -
Rapid Response Innovation Awards, 2008Nicotinic receptor agonists and L-dopa-induced dyskinesias
Objective/Rationale:
Levodopa is one of the most effective therapies for Parkinson’s disease. However, its use is associated with the development of abnormal involuntary movements or dyskinesias that... -
Rapid Response Innovation Awards, 2008Modeling Studies of Several Drug Molecules and their Derivatives for Treatment of Parkinson's Disease
Objective/Rationale:
Parkinson’s treatment on the molecular level involves the removal of the insoluble protein molecules called the ‘Lewy bodies’ formed by the misfolding of these proteins.This can be... -
Rapid Response Innovation Awards, 2008Unraveling the Genetic Basis for Alpha-Synuclein Oligomerization in Living Cells Using Bimolecular Fluorescence Complementation
Promising Outcomes of Original Grant:
The formation of large alpha-synuclein protein inclusions in the brain is the pathological hallmark of Parkinson’s disease but whether those inclusions are the... -
Rapid Response Innovation Awards, 2008Understanding and Modeling the Complexity of Sporadic Parkinson's Disease: Genetic and Environmental Factors
Promising Outcomes of Original Grant:
As mutations in the glucocerebrosidase (GBA) gene are considered to be a risk factor for sporadic Parkinson's disease, we developed a mutant preclinical model with...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.